Drug Trial Radar · NCT04625361
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Jan 20, 2021
Primary completion
Jan 6, 2022
Study completion Jan 6, 2022
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in Healthy Subjects
Conditions
- Parkinson Disease
Interventions
HEC122505MsOHDrug
Part2:Mulltiple doses once daily, up to 8 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Adverse Events (AEs)Time frame: Part 1:up to 6 days; Part 2: up to 13 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.